SE8701437D0 - DIAGNOSTIC PROCEDURE IN VITRO AND MEDICINES THAT CAN BE USED BY THE PROCEDURE - Google Patents

DIAGNOSTIC PROCEDURE IN VITRO AND MEDICINES THAT CAN BE USED BY THE PROCEDURE

Info

Publication number
SE8701437D0
SE8701437D0 SE8701437A SE8701437A SE8701437D0 SE 8701437 D0 SE8701437 D0 SE 8701437D0 SE 8701437 A SE8701437 A SE 8701437A SE 8701437 A SE8701437 A SE 8701437A SE 8701437 D0 SE8701437 D0 SE 8701437D0
Authority
SE
Sweden
Prior art keywords
procedure
vitro
elastase
value
taken
Prior art date
Application number
SE8701437A
Other languages
Swedish (sv)
Other versions
SE8701437L (en
Inventor
Tom Gustaf Per Saldeen
Rolf Kenth Sigvard Wallin
Original Assignee
Tom Gustaf Per Saldeen
Rolf Kenth Sigvard Wallin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tom Gustaf Per Saldeen, Rolf Kenth Sigvard Wallin filed Critical Tom Gustaf Per Saldeen
Priority to SE8701437A priority Critical patent/SE8701437L/en
Publication of SE8701437D0 publication Critical patent/SE8701437D0/en
Priority to EP88903441A priority patent/EP0353242A1/en
Priority to JP63503362A priority patent/JPH02503033A/en
Priority to PCT/SE1988/000167 priority patent/WO1988008134A1/en
Priority to AU15961/88A priority patent/AU1596188A/en
Publication of SE8701437L publication Critical patent/SE8701437L/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6884—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from lung
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen

Abstract

Method for the in vitro diagnostication of diseases associated with fibrin(ogen)olysis and/or pathological elastase activity, characterized in that a sample taken from a patient and containing fibrinopeptides is subjected to quantification of at least one elastase induced B beta 14(+/-2) - 45(+/-3) fibrinopeptide(s). The value thus obtained is compared with a normal value for healthy individuals, and that if the value obtained is higher than said normal value the patient from whom the sample has been taken is classed as being diseased. The assay method provides a way of demonstrating the presence of free elastase activity in samples taken from patients. Furthermore, novel antibody preparations as well as novel elastase induced B beta 14(+/-2) - 45(+/-3) fibrinopeptide preparations are described which may be employed in the said method.
SE8701437A 1987-04-06 1987-04-06 IN VITRO DIAGNOSTIC PROCEDURE AND MEASURES THAT CAN BE USED IN THE PROCEDURE SE8701437L (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
SE8701437A SE8701437L (en) 1987-04-06 1987-04-06 IN VITRO DIAGNOSTIC PROCEDURE AND MEASURES THAT CAN BE USED IN THE PROCEDURE
EP88903441A EP0353242A1 (en) 1987-04-06 1988-04-05 METHOD AND MEANS FOR DIAGNOSTIC DETECTION OF ELASTASE DERIVED B-beta FIBRINOPEPTIDES
JP63503362A JPH02503033A (en) 1987-04-06 1988-04-05 In vitro diagnostic methods and means useful therefor
PCT/SE1988/000167 WO1988008134A1 (en) 1987-04-06 1988-04-05 METHOD AND MEANS FOR DIAGNOSTIC DETECTION OF ELASTASE DERIVED Bbeta-FIBRINOPEPTIDES
AU15961/88A AU1596188A (en) 1987-04-06 1988-04-05 Method and means for diagnostic detection of elastase derived Bbeta-fibrino peptides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8701437A SE8701437L (en) 1987-04-06 1987-04-06 IN VITRO DIAGNOSTIC PROCEDURE AND MEASURES THAT CAN BE USED IN THE PROCEDURE

Publications (2)

Publication Number Publication Date
SE8701437D0 true SE8701437D0 (en) 1987-04-06
SE8701437L SE8701437L (en) 1988-10-07

Family

ID=20368117

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8701437A SE8701437L (en) 1987-04-06 1987-04-06 IN VITRO DIAGNOSTIC PROCEDURE AND MEASURES THAT CAN BE USED IN THE PROCEDURE

Country Status (5)

Country Link
EP (1) EP0353242A1 (en)
JP (1) JPH02503033A (en)
AU (1) AU1596188A (en)
SE (1) SE8701437L (en)
WO (1) WO1988008134A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345906B1 (en) * 1988-06-10 1996-03-13 Merck & Co. Inc. Unique elastase induced fibrinogen cleavage site antigens
US6124107A (en) * 1988-06-10 2000-09-26 Merck & Co., Inc. Assay for marker of human polymorphonuclear leukocyte elastase activity
WO2006101436A1 (en) * 2005-03-22 2006-09-28 Astrazeneca Ab A peptide fingerprint from the de radation of elastin by hne
CN108473559A (en) * 2015-11-10 2018-08-31 威特拉公司 Specifically bind antibody molecule-drug conjugate and its application of lipopolysaccharides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722903A (en) * 1983-11-14 1988-02-02 New York Blood Center, Inc. Monoclonal antibodies specific to in vivo fragments derived from human fibrinogen, human fiberin I or human fibrin II
DE3400434A1 (en) * 1984-01-09 1985-09-26 Behringwerke Ag, 3550 Marburg DETERMINATION OF FIBRINE WITH FIBRINE-SPECIFIC ANTIBODY

Also Published As

Publication number Publication date
AU1596188A (en) 1988-11-04
WO1988008134A1 (en) 1988-10-20
SE8701437L (en) 1988-10-07
EP0353242A1 (en) 1990-02-07
JPH02503033A (en) 1990-09-20

Similar Documents

Publication Publication Date Title
DE3771185D1 (en) OPTICAL DETECTOR FOR THE SIMULTANEOUS DETECTION OF HEARTBEAT AND TORAXIAL MOVEMENT.
DE69110098T2 (en) Test strips for the visual determination of the blood glucose concentration.
AU8040787A (en) Automated patient sample analysis instrument
ATE253631T1 (en) A THROMBIN BLOOD FRACTION FOR USE IN A MEDICAL PROCEDURE
DK552684A (en) DESULPHATO HIRUDINES AND THEIR PREPARATION AND USE
ATE54826T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING THYMUS EXTRACT FRACTIONS.
ATE168135T1 (en) DIAGNOSIS OF RETINOBLASTOMA
ATE84877T1 (en) METHODS FOR CRYSTAL MORPHOLOGICAL BLOOD AND URINAL ANALYSIS, FOR EARLY DIAGNOSIS AND FOR THE MANUFACTURE OF MEDICINES.
DE69019886T2 (en) Catheters and instruments for extracorporeal circulation.
DE3783966D1 (en) REAGENTS FOR THE EXAMINATION OF PERIODENTAL DISEASES.
DE3870405D1 (en) TEST DEVICE FOR DETERMINING OCCULT BLOOD AND GLUCOSE.
DE3583875D1 (en) METHOD FOR PRODUCING SPHERICAL WHOLE BLOOD ERYTHROCYTES AND FIXING THEREOF.
ATE86633T1 (en) SNRNP-A ANTIGEN AND FRAGMENTS THEREOF.
ATE48142T1 (en) BLOOD PROTEIN, PROCESS FOR ITS PRODUCTION, ANTIBODIES TO THIS PROTEIN AND THIS PROTEIN OR PHARMACEUTICAL PREPARATIONS CONTAINING THESE ANTIBODIES.
SE8701437D0 (en) DIAGNOSTIC PROCEDURE IN VITRO AND MEDICINES THAT CAN BE USED BY THE PROCEDURE
IT1148290B (en) PROCESS AND REAGENT FOR THE PHOTOMETRIC DETERMINATION OF THE BLOOD HEMOGLOBIN CONTENT
IT1203671B (en) REAGENT FOR THE DETERMINATION OF THE BLOOD COAGULATION FUNCTION AND PROCEDURE FOR ITS PREPARATION
IT8423926A0 (en) DIAGNOSTIC METHOD FOR THE ASSESSMENT OF CLINICAL PARAMETERS THROUGH DIRECT SAMPLING OF BIOLOGICAL MATERIALS AND DEVICE FOR ITS IMPLEMENTATION.
DE3852625D1 (en) Vectors and compounds for the expression of zymogen forms of human protein C.
ATE108906T1 (en) METHOD OF DETERMINING THE BEHAVIOR OF DRUGS IN LIVING THINGS.
FI844645A0 (en) 1,7-DIPHENYL-3-METHYLAZA-7-CYAN-8-METHYL-NONAN FOR ANALYSIS OF THE CONSTRUCTION OF SJUKDOMAR.
DE3850933D1 (en) Anticoagulant protein PP4-X, its production and use.
EP0253255A2 (en) Method and test kit for the detection of fibrin monomers in the blood
DE3872790D1 (en) DEVICE FOR THE EXAMINATION OF ZIPPER ELEMENTS.
AU3065789A (en) Clinical testing, monitoring and pharmaceutical compositions for treatment of auto-immune diseases